Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-11-12
2004-09-07
Harris, Alana M. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S001110, C536S018700, C536S022100, C536S023100, C530S300000, C530S350000
Reexamination Certificate
active
06787646
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates generally to proliferative diseases such as cancer and, more specifically, to tumor suppressor molecules that can be used to diagnose and treat proliferative diseases.
Cancer is one of the leading causes of death in the United States. Each year, more than half a million Americans die from cancer, and more than one million are newly diagnosed with the disease. Cancerous tumors result when a cell escapes from its normal growth regulatory mechanisms and proliferates in an uncontrolled fashion. Tumor cells can metastasize to secondary sites if treatment of the primary tumor is either not complete or not initiated before substantial progression of the disease. Early diagnosis and effective treatment of tumors is therefore essential for survival.
Cancer involves the clonal replication of populations of cells that have gained competitive advantage over normal cells through the alteration of regulatory genes. Regulatory genes can be broadly classified into “oncogenes” which, when activated or overexpressed promote unregulated cell proliferation, and “tumor suppressor genes” which, when inactivated or underexpressed fail to prevent abnormal cell proliferation. Loss of function or inactivation of tumor suppressor genes is thought to play a central role in the initiation and progression of a significant number of human cancers.
A number of tumor suppressor genes have been identified that, when inactivated, are involved in the initiation or progression of human cancers. Known tumor suppressor genes include, for example, RB, p53, DCC, APC/MCC, NF1, NF2, WT1, VHL, BRCA1, MST1 and WAF1/CIP1. Approaches for treating cancer by modulating the function of certain of these tumor suppressor genes, either with pharmaceutical compounds or by gene therapy methods, have yielded promising results in animal models and in human clinical trials.
Approaches for diagnosing and prognosing cancer by identifying mutations in known tumor suppressor genes have also been developed. For example, identifying individuals containing germline mutations in known tumor suppressor genes has permitted the identification of individuals at increased risk of developing cancer. Such individuals are then closely monitored or treated prophylactically to improve their chance of survival. Identifying the pattern of alterations of known tumor suppressor genes in biopsy samples is also being used to determine the presence or stage of a tumor. Being able to determine whether a cancer is benign or malignant, at an early or late stage of progression, provides the patient and clinician with a more accurate prognosis and can be used to determine the most effective treatment.
In view of the importance of tumor suppressor molecules in the detection and treatment of cancer, there exists a need to identify additional tumor suppressor nucleic acids and polypeptides. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF INVENTION
The invention provides substantially pure tumor suppressor nucleic acid molecules. In one embodiment, the invention provides a substantially pure tumor suppressor nucleic acid molecule having at least fifteen contiguous nucleotides of SEQ ID NO:2, or a functional fragment thereof. In another embodiment, the invention provides a substantially pure nucleic acid molecule having substantially the same nucleic acid sequence as SEQ ID NO:5, or a functional fragment thereof. In yet another embodiment, the invention provides a substantially pure tumor suppressor nucleic acid molecule having at least fifteen contiguous nucleotides of SEQ ID NO:4, or a functional fragment thereof.
The invention also provides substantially pure hairpin ribozyme nucleic acid molecules, containing a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3.
The invention further provides a substantially pure tumor suppressor polypeptide having substantially the same amino acid sequence as SEQ ID NO:6, or a functional fragment thereof. A substantially pure antibody or antigen binding fragment reactive with the tumor suppressor polypeptide is also provided.
Also provided are methods of detecting a neoplastic cell in a sample. In one embodiment, the method consists of contacting the sample with a detectable agent specific for a tumor suppressor nucleic acid of the invention and detecting the nucleic acid molecule in the sample, wherein altered expression or structure of the nucleic acid molecule indicates the presence of a neoplastic cell in said sample. In another embodiment, the method consists of contacting the sample with a detectable agent specific for a tumor suppressor polypeptide of the invention and detecting the polypeptide in the sample, wherein altered expression or structure of the polypeptide indicates the presence of a neoplastic cell in the sample.
REFERENCES:
patent: 5821118 (1998-10-01), Omer et al.
patent: WO 97/46675 (1997-11-01), None
patent: WO/98 32880 (1998-07-01), None
patent: WO 99/02675 (1999-01-01), None
patent: WO/99 53031 (1999-10-01), None
patent: WO/00 05415 (2000-02-01), None
patent: WO/00 15799 (2000-03-01), None
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Molecular and Cellular Biology 8(3): 1247-12552, Mar. 1988.*
Malkin, D. The role of p53 in human cancer. J. Neurooncol. 51(3): 231-243, Feb. 2001.*
GenCore, nucleic acid database sheets for U.S. Pat. No. 5,821,118 disclosing SEQ ID No: 2 and SEQ ID No: 18, two sheets, Oct. 13, 1998.*
GenCore, nucleic acid database sheets for WO 97/46675, Accession No. AAV10266, two sheets, Jun. 3, 1998.*
GenCore, nucleic acid database sheets for WO 99/02675, Accession No. AAX07369, four sheets, Jun. 7, 1999.*
GENBANK AA495929 (Jun. 30, 1997).
GENBANK AA583557 (Sep. 5, 1997).
GENBANK AI247609 (Nov. 4, 1998).
GENBANK AB016160 (Jan. 22, 1999).
GENBANK AF030453 (Nov. 24, 1998).
GENBANK AB016161 (Jan. 22, 1999).
GENBANK AC003104 (Jun. 25, 1998).
GENBANK AI078456 (Aug. 10, 1998).
GENBANK Z54280 (Jan. 15, 1997).
GENBANK AI084732 (Aug. 17, 1998).
GENBANK AC005739 (Oct. 1, 1998).
GENBANK AI147476 (Sep. 29, 1998).
GENBANK X68128 (Jun. 1, 1994).
GENBANK C73064 (Sep. 22, 1997).
GENBANK Z98755 (Nov. 23, 1999).
GENBANK D24303 (Dec. 2, 1993).
GENBANK R12420 (Apr. 12, 1995).
GENBANK D42474 (May 4, 1998).
GENBANK AI359294 (Jan. 6, 1999).
GENBANK D46041 (Mar. 9, 1995).
GENBANK AC006022 (Dec. 21, 1999).
GENBANK H28699 (Jul. 14, 1995).
GENBANK AB014571 (Feb. 6, 1999).
GENBANK T92983 (Mar. 22, 1995).
GENBANK AA406194 (May 1, 1997).
GENBANK W84786 (Sep. 6, 1996).
GENBANK AA278399 (Apr. 2, 1997).
GENBANK W84833 (Sep. 6, 1996).
GENBANK AI147481 (Sep. 29, 1998).
GENBANK AA211219 (Jan. 16, 1997).
GENBANK L00634 (Jun. 12, 1993).
GENBANK AA571392 (Aug. 27, 1997).
GENBANK L10413 (Jan. 30, 1996).
GENBANK AA160809 (Jun. 24, 1997).
GENBANK D29973 (Feb. 7, 1999).
GENBANK S69381 (Sep. 23, 1994).
GENBANK AA511830 (Jul. 8, 1997).
GENBANK Z82189 (Dec. 12, 1999).
GENBANK AA474138 (Jun. 18, 1997).
GENBANK AC005165 (Jun. 20, 1998).
GENBANK C85533 (Mar. 2, 1998).
GENBANK AA408534 (May 2, 1997).
GENBANK AA408064 (May 2, 1997).
GENBANK C87343 (Mar. 2, 1998).
GENBANK AI326830 (Dec. 23, 1998).
GENBANK AA070605 (Oct. 27, 1997).
GENBANK AA655540 (Nov. 4, 1997).
GENBANK AC003957 (Dec. 29, 1997).
GENBANK AC003695 (Oct. 29, 1998).
GENBANK U09941 (Mar. 14, 1995).
GENBANK AC002091 (May 13, 1997).
GENBANK X64080 (Dec. 15, 1997).
GENBANK X98523 (Oct. 30, 1996).
GENBANK D26094 (Dec. 3, 1993).
GENBANK AJ011930 (Nov. 11, 1998).
GENBANK Y00057 (Jul. 28, 1995).
GENBANK AC005668 (Sep. 10, 1998).
GENBANK M15395 (Jan. 6, 1995).
GENBANK U94776 (Jun. 1, 1998).
GENBANK AA158729 (Jun. 24, 1997).
GENBANK AA357439 (Apr. 21, 1997).
GENBANK AA600873 (Sep. 23, 1997).
GENBANK W87345 (Jun. 24, 1996).
GENBANK AB000909 (Apr. 7, 1998).
GENBANK AA492602 (Jun. 25, 1997).
GENBANK AF067845 (Feb. 8, 1999).
GENBANK AI325663 (Dec. 23, 1998).
GENBANK AA575760 (Sep. 21, 1997).
GenBank Accession No.: AF102805, Mar. 3, 1999.
GenBank Accession No.: AF043700, Jan. 22, 1
Barber Jack R.
Welch Peter J.
Harris Alana M.
Immusol Inc.
LandOfFree
Tumor suppressor molecules and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor suppressor molecules and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor suppressor molecules and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3185162